Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5643_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •1.1 Introduction
- •1.2 The Evolution of Herbal Medicine: A Historical Perspective
- •1.3 Diversity of Herbal Pharmacopoeias Across the Globe
- •1.3.1 The Indian Pharmacopoeia (IP)
- •1.3.2 The European Pharmacopoeia (Ph. Eur.)
- •1.3.3 United States Pharmacopoeia (USP)
- •1.3.4 The Russian Federation’s State Pharmacopoeia (SPRF)
- •1.3.6 Hausa Herbal Pharmacopoeia
- •1.5 Ayurveda and the Integration of Nanotechnology
- •1.6 Enhancing Herbal Medicines Through Nanotechnology
- •1.7 Approaches of Nanotechnology in Herbal Medicine
- •1.7.1 Solid Lipid Nanoparticles (SLN)
- •1.7.2 Nanoemulsions
- •1.7.3 Liposomes
- •1.7.4 Ethosomes, Transferosomes, and Transethosomes
- •1.7.5 Niosomes and Phytosomes
- •1.7.6 Micelles, Dendrimers, and Nanostructured Lipid Carriers (NLCs)
- •1.7.7 Nanoparticles, Nanocapsules, and Nanogels
- •1.8 Types of Novel Drug Delivery Systems (NDDS)
- •1.9 Nanotechnology and Its Applications
- •1.10 Efficacy and Safety of Herbal Medicine
- •1.11 Concept of Bhasma and Nanotechnology
- •1.11.1 Nanoparticle Nature of Bhasma
- •1.3.5 Romanian Pharmacopoeia (RPh)
- •1.12 Supermolecules and Nanotechnology
- •1.14 Future Prospects of Nanomedicines
- •1.15 Conclusion
- •References
- •2.1 Introduction
- •2.2 Prehistory
- •2.2.1 Ancient Civilization
- •2.2.1.1 Mesopotamia
- •2.2.1.2 Ancient Egypt
- •2.2.1.3 India, China, Greece, & Rome
- •2.2.1.3.1 India
- •2.2.1.3.2 China
- •2.2.1.3.3 Greece and Rome
- •2.3 Middle Ages and Beyond
- •2.3.1 Translation of Herbals
- •2.3.2 Early Modern Era
- •2.4 Modern Times
- •2.5 Current Status
- •2.6 Challenges Associated
- •2.6.1 Regulation and Safety of Herbal Medications
- •2.6.2 Quality Control of Herbal Medicine
- •2.6.3 Safety Monitoring of Herbal Medicines
- •2.6.4 Bioavailability of Herbal Medicines
- •2.6.5 Clinical Trials
- •2.7 Future Perspectives
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Herbal Extraction
- •3.2.2 Choice: Solvent Selection of a Suitable Medium
- •3.3 Supercritical Fluid Extraction (SFE)
- •3.3.1 Working Principle of SFE
- •3.3.2 Parts of the SFE System
- •3.3.3 Process of extraction
- •3.3.4 Applications
- •3.4 Microwave-Assisted Extraction (MAE)
- •3.4.1 Working Principle
- •3.4.2 Components of a Microwave-Assisted Extraction System
- •3.4.3 Method of Extraction from Herbs by MAE
- •3.5 Ultrasound-Assisted Extraction (UAE)
- •3.5.1 Working Principle
- •3.9.3 Applications of GC-MS in Herbal Analysis
- •3.9.4 Endowed Oil Analysis
- •3.9.5 Alkaloids and Phenolic Compounds
- •3.9.6 Terpenoids
- •3.9.7 Quantitative Analysis
- •3.9.8 Data Analysis and Interpretation
- •3.10 Liquid Chromatography-Mass Spectrometry (LC-MS)
- •3.10.1 Principles of Liquid Chromatography-Mass Spectrometry
- •3.5.1.1 Cell Disruption
- •3.5.1.2 Increased Mass Transport
- •3.5.1.3 Enhanced Solvent Effectiveness
- •3.5.2 Parts of the Ultrasound-Assisted Extraction System
- •3.5.3 Method of Extraction from Herbs
- •3.6 Pressurized Liquid Extraction (PLE)
- •3.6.1 Definition
- •3.6.2 Working Principle
- •3.6.3 Parts of the PLE System
- •3.6.4 PLE Extraction Method
- •3.7 Subcritical Water Extraction (SWE)
- •3.7.1 Supercritical fluids
- •3.7.2 Supercritical Fluid Extraction (SFE)
- •3.7.3 Working Principle of Subcritical Water Extraction (SWE)
- •3.7.4 Parts of the Subcritical Water Extraction System
- •3.7.5 Process of Subcritical Water Extraction
- •3.8 High-Performance Liquid Chromatography (HPLC)
- •3.8.1 Principles of HPLC
- •3.8.2 Bioactive Compounds Analysis
- •3.8.2.1 Phenolic Compounds
- •3.8.2.2 Alkaloids
- •3.8.2.3 Terpenoids
- •3.8.3 Recent Advances in HPLC Techniques
- •3.8.3.1 Ultra-High-Performance Liquid Chromatography
- •3.8.3.2 HPLC-MS
- •3.8.3.3 Chiral HPLC
- •3.8.4 Applications of Herbal Medicine
- •3.8.4.1 Quality Control
- •3.8.4.2 Pharmacokinetic
- •3.8.4.3 Challenges and Prospects for Further Study
- •3.9 Gas Chromatography-Mass Spectrometry (GC-MS)
- •3.9.1 Principles of GC-MS
- •3.9.2 Sample Preparation
- •3.10.2 Methods for LC-MS Detection Analysis
- •3.10.2.1 Applications of LC-MS in Herbal Analysis
- •3.10.3 Principles of FTIR
- •3.10.4 Application of FTIR in Herb Analysis
- •3.10.5 Phytochemical Identification
- •3.10.6 Quantitation of Bioactive Compounds
- •3.10.7 Structural Elucidation
- •3.10.8 Sample Preparation for FTIR Analysis
- •3.10.9 Direct Analysis
- •3.10.10 Extraction
- •3.10.11 Pellet Preparation
- •3.10.12 Thin Films
- •3.10.13 Data Analysis and Interpretation
- •3.10.14 Advantages of FTIR on Herb Analysis
- •3.10.15 Non-Destructive
- •3.10.16 Fast and Easy
- •3.10.17 Rich Information
- •3.10.18 Versatility
- •3.10.19 Cost-Effective
- •3.10.20 FTIR Limitations and Low Sensitivity
- •3.10.21 Overlapping Bands
- •3.10.22 Preparation of the Sample
- •3.10.23 Conclusion
- •3.11 Nuclear Magnetic Resonance Spectroscopy (NMR)
- •3.11.1 Sample Preparation and Instrumentation
- •3.11.2 One-Dimensional NMR Spectroscopy
- •3.11.3 Two-Dimensional NMR Spectroscopy
- •3.11.4 Phytochemical Applications
- •3.11.6 Techniques of Standardization
- •3.11.7 Extraction and Analysis of Bioactive Compounds
- •3.11.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Historical Context of Plant-Based Medicines
- •4.2.2 Development of Pharmacognosy
- •4.2.3 Impact of Plant-Based Medicines on Modern Pharmacology
- •4.3.1 Integration of Ethnobotanical Knowledge
- •4.3.2 Advanced Phytochemical Techniques
- •4.3.3 Bioassay-Guided Fractionation
- •4.3.4 Role of Metabolomics and Genomics
- •4.3.5 Integration of Nanotechnology
- •4.4 Ethnobotanical Approaches
- •4.4.1 Traditional Knowledge and Indigenous Applications
- •4.4.2 Ethnopharmacological Surveys and Their Relevance
- •4.5 Phytochemical Techniques
- •4.5.1 Methods of Plant Extraction and Isolation
- •4.5.1.1 Solvent Extraction
- •4.5.1.2 Supercritical Fluid Extraction (SFE)
- •4.5.1.3 Microwave-Assisted Extraction (MAE)
- •4.5.1.4 Ultrasound-Assisted Extraction (UAE)
- •4.5.1.5 Enzyme-Assisted Extraction (EAE)
- •4.6 Bioassay-Guided Fractionation
- •4.6.1 Fractionation Techniques
- •4.6.2 Biological Assays
- •4.6.3 Iterative Purification
- •4.7.1 High-Performance Liquid Chromatography (HPLC)
- •4.7.2 Gas Chromatography-Mass Spectrometry (GC-MS)
- •4.7.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
- •4.7.4 Fourier Transform Infrared (FTIR) Spectroscopy
- •4.7.5 Metabolomics and Genomics in Plant Drug Discovery
- •4.8 Role of Metabolomics in Identifying Bioactive Compounds
- •4.8.1 Identification of Bioactive Compounds
- •4.8.2 Explanation of Biosynthetic Pathways
- •4.8.3 Discovery of Biosynthetic Genes
- •4.8.4 Enhancement of Phytochemical Production
- •4.9 Case Studies of Genomic Applications in Drug Discovery
- •4.9.1 Case Study 1: Artemisinin Production in Artemisia annua
- •4.9.2 Case Study 2: Taxol Biosynthesis in Taxus spp.
- •4.9.3 Case Study 3: Resveratrol Production in Vitis vinifera
- •4.10 Biotechnological Advances
- •4.10.1 Tissue Culture and the Genetic Modification of Medicinal Plants
- •4.10.2 Sustainable Production of Phytochemicals through Biotechnology
- •4.10.3 Role of Synthetic Biology in Plant-Based Drug Development
- •4.11 Nanotechnology in Phytochemical Delivery
- •4.11.1 Enhancing the Bioavailability of Plant-Derived Drugs with Nanocarriers
- •4.11.1.1 Nanoparticles
- •4.11.1.2 Liposomes
- •4.11.1.3 Nanoemulsions
- •4.11.2 Targeted Delivery Systems Using Nanotechnology
- •4.11.2.1 Active Targeting
- •4.11.2.2 Passive Targeting
- •4.11.2.3 Multifunctional Nanocarriers
- •4.11.3 Case Studies of Nano-Formulated Phytochemicals
- •4.11.3.1 Curcumin-Loaded Nanoparticles
- •4.11.3.2 Quercetin-Loaded Liposomes
- •4.11.3.3 Resveratrol-Functionalized Gold Nanoparticles
- •4.11.3.4 Nanoemulsion Formulations of Essential Oils
- •4.12.1 Paclitaxel (Taxol)
- •4.12.2 Artemisinin
- •4.12.3 Morphine
- •4.12.4 Quinine
- •4.12.5 Challenges and Limitations in Plant-Based Drug Development
- •4.12.5.1 Complexity of Plant Extracts
- •4.12.5.2 Variability in Chemical Composition
- •4.12.5.3 Sustainable Sourcing and Conservation
- •4.12.5.4 Regulatory and Approval Processes
- •4.12.6 Intellectual Property and Benefit Sharing
- •4.13 Future Perspectives
- •4.13.1 Emerging Trends in Plant-Based Drug Discovery
- •4.13.2 Integrating Traditional Knowledge with Modern Science
- •4.13.3 Potential of Plant Genomics and Biotechnology
- •4.14 Conclusion
- •References
- •5.1 Introduction
- •5.2 Traditional Phytomedicine
- •5.3 Modern Phytomedicine
- •5.4 Synthesis and Purpose of Bioactive Compounds
- •5.5.1 Phenolic Compounds (PCs)
- •5.5.2 Terpenes
- •5.5.3 Nitrogen-Containing Compounds
- •5.6 Extraction of Bioactive Compounds
- •5.7 Role of Herbs in Drug Discovery
- •5.8 Global Trade of Herbal Medicines
- •5.9.1 Herbal Compounds for the Human Immune System
- •5.9.2 Bioactive Compounds in Herbs For Cancer Treatment
- •5.9.3 Bioactive Compounds for Neurodegenerative Diseases
- •5.9.4 Bioactive Compounds for Viral Diseases
- •5.9.5 Anti-Inflammatory Bioactive Compounds in Herbs
- •5.9.6 Antidiabetic Bioactive Compounds in Herbs
- •5.9.7 Antibiotics
- •5.10 Summary
- •References
- •6.1 Introduction
- •6.1.2 Antibiotic-Resistant Microorganisms
- •6.1.3 Necessity of Developing Natural Plant-Derived Drugs
- •6.2 Pharmacological Activities of Medicinal Plants
- •6.2.1 Antimicrobial Activity of Herbal Drugs
- •6.2.2 Anticancer Activity of Medicinal Herbs
- •6.2.3 Antiviral Activity of Medicinal Herbs
- •6.2.3.1 Medicinal Plants Exhibiting Antiviral Activity
- •6.2.4 Antioxidant Activity of Medicinal Herbs
- •6.2.5 Hepatoprotective Activity of Medicinal Herbs
- •6.2.6 Nervous System Activity of Medicinal Herbs
- •6.2.7 Anti-Inflammatory Activity of Medicinal Herbs
- •6.2.7.1 Mechanism of Action
- •6.2.8 Antipyretic Activity of Medicinal Herbs
- •6.2.8.1 Medicinal Plants Possessing Antipyretic Properties
- •6.2.9 Antiallergic Activity of Medicinal Herbs
- •6.2.10 Antidiabetic Activity of Medicinal Herbs
- •6.2.10.1 Medicinal Plants Possessing Antidiabetic Activity
- •6.2.11 Immunomodulatory Activity of Medicinal Herbs
- •6.3 Advantages of Medicinal Herbs
- •6.4 Disadvantages of Medicinal Herbs
- •6.5 Future Prospects of Medicinal Herbs
- •References
- •7.1 Introduction to Herbal Drug Discovery
- •7.1.1 History of Herbal Drug Discovery
- •7.2 Current trends in herbal drug discovery
- •7.2.1 Molecular and Genetic Study Levels
- •7.2.2 Molecular Pharmacognosy
- •7.2.3 Combination Therapy
- •7.2.4 Conservation and Propagation Strategies
- •7.2.5 Pharmacogenomics
- •7.2.6 Computational Resources for Drug Discovery
- •7.4.1 Metabolomics Approaches in Herbal Drug Discovery
- •7.4.2 Genomic Approaches
- •7.5.1 Quinine for Malarial Treatment
- •7.5.2 Aspirin for Pain and the Treatment of Inflammation
- •7.6 Limitations in Herbal Drug Discovery
- •7.6.1 Regulatory Hurdles
- •7.6.2 Emerging Technologies
- •References
- •8.1 Introduction
- •8.2 Traditional Approaches to Herbal Formulation
- •8.3 Phytochemical Constituents in Herbal Formulations
- •8.3.1 Alkaloids
- •8.3.2 Flavonoids
- •8.3.3 Terpenoids
- •8.3.4 Glycosides
- •8.3.5 Tannins
- •8.3.6 Phenolic Acids
- •8.3.7 Saponins
- •8.4 Modern Extraction Techniques in Herbal Formulation
- •8.4.1 Solvent Extraction
- •8.4.2 Supercritical Fluid Extraction (SFE)
- •8.4.3 Ultrasonic Extraction
- •8.4.4 Microwave-Assisted Extraction (MAE)
- •8.4.5 Enzyme-Assisted Extraction (EAE)
- •8.4.6 Comparative Analysis of Extraction Techniques
- •8.5 Advanced Formulation Strategies
- •8.5.1 Nanotechnology in Herbal Formulations
- •8.5.1.1 Nanoemulsions
- •8.5.1.2 Liposomes
- •8.5.1.3 Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)
- •8.5.2 Encapsulation Techniques
- •8.5.2.1 Microencapsulation
- •8.5.2.2 Coacervation
- •8.5.2.3 Spray Drying
- •8.5.3 Standardized Extracts
- •8.5.3.1 Methods of Standardization
- •8.5.3.2 Challenges in Standardization
- •8.5.4 Synergistic Formulations
- •8.5.4.1 Mechanisms of Synergy
- •8.5.4.2 Examples of Synergistic Formulations
- •8.5.5 Personalized Herbal Formulations
- •8.5.5.1 Role of Genomics in Personalized Herbal Medicine
- •8.5.5.2 Challenges in Personalized Herbal Formulations
- •8.6.1 Recognition and Verification of Herbal Materials
- •8.6.1.4 DNA Barcoding
- •8.6.2 Use of Reference Standards
- •8.6.2.1 Primary and Secondary Reference Standards
- •8.6.2.2 Development of Reference Standards
- •8.6.3 Good Manufacturing Practices (GMP)
- •8.6.3.1 Sourcing and Handling of Raw Materials
- •8.6.3.2 Manufacturing Processes
- •8.6.3.3 Quality Control Testing
- •8.6.3.4 Documentation and Record-Keeping
- •8.7 Challenges in Herbal Formulation Development
- •8.7.1 Variability in Chemical Composition
- •8.7.1.1 Factors Affecting Chemical Composition
- •8.7.1.2 Strategies to Address Variability
- •8.7.2 Complexity of Herbal Extracts
- •8.7.2.1 Analytical Challenges
- •8.7.2.2 Formulation Challenges
- •8.7.3 Standardization of Herbal Formulations
- •8.7.3.1 Challenges in Standardization
- •8.7.3.2 Advances in Standardization
- •8.7.4 Regulatory Hurdles
- •8.7.4.1 Regulatory Requirements
- •8.7.4.2 Challenges in Meeting Regulatory Requirements
- •8.7.4.3 Strategies to Overcome Regulatory Hurdles
- •8.8 Future Directions in Herbal Formulation Development
- •8.8.1 Artificial Intelligence and Machine Learning
- •8.8.1.1 Applications in Herbal Formulation Development
- •8.8.1.2 Challenges and Opportunities
- •8.8.2 Integration of Omics Technologies
- •8.8.2.1 Applications in Herbal Medicine
- •8.8.2.2 Challenges and Opportunities
- •8.8.3 Novel Delivery Systems
- •8.8.3.1 Nanotechnology in Herbal Medicine
- •8.8.3.2 Other Novel Delivery Systems
- •8.8.3.3 Challenges and Opportunities
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Herbal Nanotechnology and Phytonanomedicines
- •9.2.1 Role of Phytonanomedicines in Disease Management
- •9.2.1.1 Cancer
- •9.2.1.2 Diabetes Mellitus
- •9.2.1.3 Neurodegenerative Diseases (NDDs)
- •9.2.1.4 Cardiovascular Diseases (CVD)
- •9.3 Nanoparticles for Plant Disease Management
- •9.3.1 Role of Silver Nanoparticles (AgNPs) in Plant Disease Management
- •9.3.2 Role of Gold Nanoparticles (AuNPs) in Plant Disease Management
- •9.3.3 Role of Zinc Nanoparticles (ZnNPs) in Plant Disease Management
- •9.3.4 Role of Palladium Nanoparticles (PdNPs) in Plant Disease Management
- •9.3.5 Role of Titanium Nanoparticles (TiNPs) in Plant Disease Management
- •9.3.6 Role of Iron Nanoparticles (FeNPs) in Plant Disease Management
- •9.3.7 Role of Copper Nanoparticles (CuNPs) in Plant Disease Management
- •9.3.8 Role of Selenium Nanoparticles (SeNPs) in Plant Disease Management
- •9.4 Nanoparticles as Carriers
- •9.4.1 Nanoparticles as Carriers for Insecticides
- •9.4.2 Nanoparticles as Carriers for Fungicides
- •9.4.3 Nanoparticles as Carriers for Herbicides
- •9.4.4 Role of Nanoparticles and RNAi in Plant Disease Management
- •References
- •10.1 Introduction
- •10.2 Types of Nanomaterials Utilized in Herbal Pharmaceuticals
- •10.2.1 Nanoparticles
- •10.2.2 Nanocapsules
- •10.2.3 Nanospheres
- •10.2.4 Nanotubes
- •10.3 Innovative Applications of Nanotechnology
- •10.3.1 Anti-Cancer Herbal Nanomedicine
- •10.3.2 Anti-Inflammatory Herbal Nanomedicine
- •10.3.3 Antibacterial Herbal Nanomedicine
- •10.3.4 Antifungal Herbal Nanomedicine
- •10.3.5 Antioxidant Neuroprotective Herbal Nanomedicine
- •10.3.6 Anti-Diabetic Herbal Nanomedicine
- •10.3.7 Cardioprotective Herbal Nanomedicine
- •10.4.1 Combining Nanotechnology and Herbal Pharmacotherapy
- •10.4.2 Enhanced Bioavailability
- •10.4.3 Targeted Delivery
- •10.4.4 Improved Stability or Shelf Life
- •10.4.5 Synergistic Effects and Combination Therapies
- •10.4.6 Reduced Dosage and Toxicity
- •10.4.7 Crossing Biological Barriers
- •10.5 Challenges and Limitations
- •10.5.1 Complexity of Herbal Systems
- •10.5.2 Bioavailability Enhancement
- •10.5.3 Regulatory and Ethical Considerations
- •10.5.4 Cost and Scalability
- •10.5.5 Safety and Toxicity Issues
- •10.5.6 Standardization and Quality Control
- •10.6 Future Prospects and Trends
- •10.7 Conclusion
- •References
- •11. Nanoparticle Synthesis and Characterization for Herbal Drug Delivery
- •11.1 Introductions
- •11.2 Background and Literature Review
- •11.2.1 Historical Overview and Present Trends in Herbal Medicine
- •11.2.2 Overview of Nanoparticles in Drug Delivery
- •11.2.3 Advantages of Nanoparticle-Based Drug Delivery Systems
- •11.3.1 Polymer Nanoparticle
- •11.3.2 Metallic Nanoparticles
- •11.3.3 Magnetic Nanoparticles
- •11.3.4 Liposomes
- •11.3.5 Dendrimers
- •11.3.6 Niosomes
- •11.3.7 Proniosomes
- •11.3.8 Phytosomes
- •11.3.9 Transfersomes
- •11.3.10 Microspheres
- •11.3.11 Ethosomes
- •11.4 Nanoparticle Synthesis Techniques
- •11.4.1 Top-Down Approach
- •11.4.2 Bottom-Up Approach
- •11.4.3 Chemical Methods
- •11.4.3.1 Sol-Gel Method
- •11.4.3.2 Spinning
- •11.4.3.3 Microemulsion Technique
- •11.4.3.4 Hydrothermal Synthesis
- •11.4.3.5 Electrochemical Synthesis
- •11.4.3.6 Polyol Synthesis
- •11.4.3.7 Thermal Decomposition
- •11.4.3.8 Chemical Vapor Deposition & Chemical Vapor Synthesis
- •11.4.3.9 Plasma-Enhanced Chemical Vapor Deposition
- •11.4.4 Physical Methods
- •11.4.4.1 High-Energy Ball Milling Process
- •11.4.4.2 Physical Vapor Deposition (PVD)
- •11.4.4.3 Pyrolysis
- •11.4.4.4 Melt Mixing
- •11.4.4.5 Laser Ablation (LA) and Pulse Laser Deposition (PLD)
- •11.4.4.6 Electron Beam Evaporation (EBE)
- •11.4.4.7 Inert Gas Condensation (IGC)
- •11.4.4.8 Flame Spray Pyrolysis (FSP)
- •11.4.4.9 Laser Pyrolysis
- •11.4.4.10 Nanolithography
- •11.4.4.11 Electrospraying Technique
- •11.4.5 Biosynthesis of Nanoparticles
- •11.4.5.1 Utilizing Biomolecules as Templates for Synthesis
- •11.4.5.2 Microbial Synthesis
- •11.4.5.3 Utilizing Botanical Extracts for Synthesis
- •11.4.6 Mechanical Techniques
- •11.5 Characterization of Nanoparticles
- •11.5.1 Chemical
- •11.5.2 Physical
- •11.5.2.1 Particle Size Analyzer
- •11.5.2.2 Surface Area Analysis
- •11.5.2.3 Zeta Potential
- •11.5.2.4 Thermogravimetric Analysis (TGA)
- •11.5.2.5 Dynamic Light Scattering
- •11.5.2.6 Scanning Electron Microscopy (SEM)
- •11.5.2.7 Nuclear Magnetic Resonance
- •11.5.2.8 Transmission Electron Microscopy (TEM)
- •11.5.2.9 X-Ray Powder Diffraction (XRD)
- •11.5.2.10 Evaluation of Recovery and Encapsulation Performance
- •11.5.2.11 Atomic Force Microscopy
- •11.5.2.12 UV-Visble Spectroscopy
- •11.5.2.13 Surface Plasmon Resonance
- •11.5.2.14 Acoustic Methods
- •11.6 Conclusion
- •References
- •12.1 Introduction
- •12.1.1 Challenges of Herbal Extracts in Traditional Medicine
- •12.1.2 Importance of Bioavailability in Therapeutic Efficacy
- •12.1.3 The Role of Nanotechnology in Addressing Bioavailability Issues
- •12.2 Principles of Bioavailability Enhancement
- •12.2.1 Understanding ADME Profiles
- •12.2.1.1 Absorption
- •12.2.1.1.1 Distribution
- •12.2.1.1.2 Metabolism
- •12.2.1.1.3 Excretion
- •12.2.2 Factors Affecting the Bioavailability of Herbal Compounds
- •12.2.2.1 Absorption within the GI Lumen
- •12.2.2.1.1 The Solubility of the Herbal Products
- •12.2.2.1.2 Absorption via Passive Diffusion
- •12.2.2.2 Metabolism
- •12.2.2.2.1 Metabolism Prior to Absorption
- •12.2.2.2.2 Metabolism Post-Absorption
- •12.2.2.3 Mechanisms of Action for Nanocarriers
- •12.3 Types of Nanocarriers and Their Applications
- •12.3.1 Liposomes: Structure, Function, and Applications
- •12.3.1.1 Structure
- •12.3.1.2 Function
- •12.3.1.3 Applications
- •12.3.2 Polymeric Nanoparticles: Design and Delivery Mechanisms
- •12.3.2.1 Design
- •12.3.2.1.1 Polymeric Material
- •12.3.2.1.2 Drug Encapsulation Methods
- •12.3.2.1.2.1 Solvent Evaporation
- •12.3.2.2 The Delivery Mechanism of the Drug
- •12.3.2.2.1 Route of Delivery
- •12.3.2.2.2 Targeting Strategies
- •12.3.2.2.2.1 Passive Targeting
- •12.3.2.2.2.2 Active Targeting
- •12.3.2.2.2.3 Stimuli-Responsive Targeting
- •12.3.2.2.3 Drug Release
- •12.3.2.2.3.1 Diffusion-Controlled Release
- •12.3.2.2.3.2 Solvent-Controlled Release
- •12.3.2.2.3.3 Chemical Interaction-Based Release
- •12.3.2.2.3.4 Temperature-Controlled Release
- •12.3.3 Nanoemulsions: Formulation and Stability
- •12.3.3.1 Formulation
- •12.3.3.1.1 The Generation of Nanoemulsion
- •12.3.3.2 Stability
- •12.3.3.2.1 Physical Stability
- •12.3.3.2.2 Chemical Stability
- •12.3.4 Micelles: Enhancing Solubility and Bioavailability
- •12.3.4.1 Enhancing Solubility and Bioavailability
- •12.3.4.1.1 Micellar Solubilization
- •12.3.4.1.2 Polymeric Micellar Nanocarriers
- •12.4 Nanocarriers and Solubility Enhancement
- •12.4.1 Techniques for Improving the Solubility of Hydrophobic Compounds
- •12.4.1.1 Lipid Dispersion Techniques
- •12.5 Stability of Herbal Extracts in Nanocarrier Systems
- •12.5.1 Protection against Degradation and Oxidation
- •12.5.2 Example of Stability Improvement in Herbal Extracts
- •12.5.2.2 Example 2: Enhancing Curcumin Stability and Bioavailability using SLNs
- •12.6 Targeted Delivery and Controlled Release
- •12.6.1 Key Principles
- •12.6.1.2 Design and Composition of Nanocarriers
- •12.6.1.2.1 Integration and Optimization
- •12.6.1.2.2 Advantages of Controlled Release Systems
- •12.6.1.2.3 Applications in Medicine
- •12.7 Pharmacokinetics and Pharmacodynamics
- •12.7.1 Enhancing Therapeutic Efficacy through Pharmacokinetic Modulation
- •12.7.1.1 Sustained Release and Targeted Delivery
- •12.7.1.2 Improved Bioavailability and Reduced Inter-Individual Variability
- •12.7.1.3 Enhanced Pharmacodynamic Effects
- •12.7.1.4 Reduced Adverse Effects and Toxicity
- •12.7.1.5 Opportunities for Personalized Medicine
- •12.7.2 Clinical Implications of Improved Pharmacodynamics
- •12.8 Clinical Applications and Case Studies
- •12.8.1 Successful Implementations of Nanocarrier-Based Herbal Drugs
- •12.8.1.1 Curcumin-Loaded Nanoparticles
- •12.8.1.2 Quercetin-Loaded Liposomes
- •12.8.1.3 Ginger Extract Nanocarriers
- •12.8.1.4 Green Tea Extract Nanocarriers
- •12.8.2 Challenges and Limitations in Clinical Settings
- •12.8.2.1 Quality Control and Standardization
- •12.8.2.2 Limited Encapsulation Capacity
- •12.8.2.3 Pharmacokinetic and Pharmacodynamic Variability
- •12.8.2.4 Manufacturing Challenges
- •12.9 Future Perspectives
- •12.9.1 Advancing Nanocarrier Design and Engineering
- •12.9.2 Expanding the Diversity of Herbal Extracts Formulated with Nanocarriers
- •12.9.3 Advancing Preclinical and Clinical Evaluation
- •12.9.4 Addressing Regulatory and Commercialization Challenges
- •12.9.5 Exploring Synergies with Other Emerging Technologies
- •12.10.1 Opportunities
- •12.10.2 Challenges
- •12.11 Conclusion
- •References
- •13.1 Introduction to Herbal Medicine and Neurological Diseases
- •13.1.1 Overview of Herbal Medicine
- •13.1.1.1 Key Aspects of Herbal Medicine
- •13.1.2 Scope of Neurological Diseases
- •13.1.3 Rationale for Exploring Herbal Remedies
- •13.2 Neuroprotective Effects of Herbal Compounds
- •13.2.1 Mechanisms of Neuroprotection
- •13.2.1.1 Antioxidant Activity
- •13.2.1.3 Inhibition of Excitotoxicity
- •13.2.1.4 Enhancement of Neurogenesis and Synaptic Plasticity
- •13.2.1.5 Mitochondrial Protection
- •13.2.2 Role of Oxidative Stress in Neurological Diseases
- •13.2.2.1 Essential Components of Oxidative Stress in Neurological Disorders
- •13.2.2.1.1 Impaired Functioning of Mitochondria
- •13.2.2.1.2 Neurological Disorders Linked to Oxidative Stress
- •13.2.3 Anti-Inflammatory Properties of Herbal Compounds
- •13.2.3.2 Uses and Advantages
- •13.2.4 Regulation of Neuronal Apoptosis by Herbal Remedies
- •13.2.4.1 Neurological Diseases Applications
- •13.2.4.2 Future Scope and Challenges of Therapy
- •13.3.1 Importance of Neurogenesis in Brain Repair
- •13.3.2 Effects of Herbal Extracts on Neurogenesis
- •13.3.3 Enhancement of Synaptic Plasticity by Herbal Compounds
- •13.4 Herbal Medicine as Adjunctive Therapy
- •13.4.1 Synergistic Effects of Herbal Compounds with Conventional Treatments
- •13.4.1.1 Cancer Care
- •13.4.1.2 Depression Relief
- •13.4.1.3 Heart Health
- •13.4.1.4 Diabetes Management
- •13.4.1.5 Pain Relief
- •13.4.2 Mitigation of Drug-Induced Side Effects
- •13.4.2.1 Digestive Challenges
- •13.4.2.2 Liver Safeguarding
- •13.4.2.3 Kidney Protection
- •13.4.2.4 Neurotoxicity
- •13.4.2.5 Cardiotoxicity
- •13.4.2.6 Bone Marrow Suppression
- •13.4.2.7 Managing Fatigue
- •13.4.3 Enhancement of Therapeutic Outcomes
- •13.5 Future Directions and Challenges
- •13.5.1 Opportunities for Further Research
- •13.5.2 Challenges in Herbal Medicine Research
- •13.5.3 Integration of Traditional Knowledge with Modern Science
- •13.6 Case Studies and Clinical Applications
- •13.6.1 Illustrative Case Studies
- •13.6.2 Clinical Applications of Herbal Medicine in Neurological Diseases
- •13.7 Conclusion
- •13.7.1 Summary of Key Findings
- •13.7.2 Future Outlook for Herbal Medicine in Neurology
- •References
- •14.1 Introduction
- •14.1.2.1 Physiochemical Characteristics and Biological Interactions
- •14.1.2.2 Potential Toxicity Concerns
- •14.1.2.3 Regulatory and Ethical Considerations
- •14.2 Preclinical Safety Assessment
- •14.2.1 In vitro Toxicity Testing
- •14.2.2 In vivo Animal Studies
- •14.2.3 Evaluating the Pharmacokinetics and Biodistribution of Nanoparticles
- •14.2.4 Immunogenicity and Biocompatibility Testing
- •14.3 Toxicological Profiling
- •14.3.1 Identification and Characterization of Possible Toxins
- •14.3.1.1 Nanoparticle Components
- •14.3.1.2 Contaminants and Impurities
- •14.3.1.3 Herbal Compounds
- •14.3.2 Dose–Response Relationships
- •14.4 Chronic Toxicity and Carcinogenicity Studies
- •14.4.1 Genotoxicity and Mutagenicity Testing
- •14.5 Clinical Safety Assessment
- •14.5.1 Phases of Clinical Trials for Nanoparticle-Based Herbal Formulation
- •14.5.2 Monitoring Adverse Effects and Long-Term Safety in Human Subjects
- •14.5.2.1 Initial Reporting Systems
- •14.5.2.2 Clinical Monitoring
- •14.5.2.3 Pharmacovigilance Networks
- •14.5.2.4 Regular Safety Updates
- •14.5.2.5 Post-Marketing Studies
- •14.5.2.6 Pharmacogenomics Studies
- •14.5.3 Post-Market Surveillance and Pharmacovigilance
- •14.5.3.1 Real-World Evidence Collection
- •14.5.3.2 Active Surveillance Programs
- •14.5.3.3 Signal Detection
- •14.5.3.4 Risk Communication
- •14.5.3.5 Regulatory Actions
- •14.6 Analytical Techniques for Safety Assessment
- •14.6.1 Advanced Imaging and Spectroscopy Methods
- •14.6.1.1 Transmission Electron Microscopy (TEM)
- •14.6.1.2 Scanning Electron Microscopy (SEM)
- •14.6.1.3 Infrared Spectroscopy (IRS)
- •14.6.2 Nanoparticle Tracking and Quantification
- •14.6.2.1 Nanoparticle Tracking Analysis (NTA)
- •14.6.2.2 Dynamic Light Scattering (DLS)
- •14.6.3 Surface Characterization and Stability Analysis
- •14.6.3.1 X-Ray Photoelectron Spectroscopy (XPS)
- •14.6.3.2 Differential Scanning Calorimetry (DSC)
- •14.6.4 High-Throughput Screening Technologies
- •14.6.4.1 Cell-Based Assay
- •14.6.4.2 Genotoxicity Screening
- •14.7 Regulatory Frameworks and Guidelines
- •14.7.1 International and National Regulatory Frameworks
- •14.7.1.1 Regulation Management
- •14.7.1.2 Risk Analysis
- •14.7.1.3 Labelling and Informed Consent
- •14.7.1.4 International Standards
- •14.7.1.5 Regulation in Research and Development
- •14.7.2 Risk Assessment Models and Safety Thresholds
- •14.7.2.1 Invitro Toxicity Assay
- •14.7.2.2 Green Algorithms
- •14.7.2.3 Nanoprobes for Measuring ROS
- •14.8 Risk Mitigation Strategies
- •14.8.1 Designing Safer Nanoparticle-Based Formulations
- •14.8.2 Controlled Release Systems and Targeted Delivery
- •14.8.3 Reducing Off-Target Effects and Enhancing Selectivity
- •14.8.3.1 Nanoparticle-Based Systems for Intracellular Targeting
- •14.8.4 Engineering Biodegradable and Biocompatible Nanoparticles
- •14.9 Case Studies of Safety Assessment
- •14.9.1 Successful Examples of Safe Nanoparticle-based Herbal Formulations
- •14.9.1.1 Curcumin-Loaded Nanoparticles
- •14.9.1.2 Green Tea Polyphenol (EGCG) Nanoparticles
- •14.9.2 Lessons Learned from Safety Failures and Recalls
- •14.10 Ethical Considerations
- •14.10.1 Ethical Issues in Nanotoxicology Research
- •14.10.2 Informed Consent and Patient Safety in Clinical Trials
- •14.11 Conclusion
- •References
- •15. Novel Drug Delivery Methods for Herbal Medicine
- •15.1 Introduction
- •15.2 Novel Drug Delivery Approaches
- •15.3 Potential of Novel Drug Delivery for Herbal Drugs
- •15.4 Types of Novel Herbal Drug Delivery Systems
- •15.4.1 Mouth-Dissolving Tablets
- •15.4.2 Controlled-Release Formulations
- •15.4.3 Liposomes
- •15.4.4 Phytosomes
- •15.4.5 Nanoparticles
- •15.4.6 Niosomes
- •15.4.7 Proniosomes
- •15.4.8 Transdermal Drug Delivery System
- •15.4.9 Microspheres
- •15.4.10 Emulsions
- •15.4.11 Ethosomes
- •15.4.12 Other Novel Approaches
- •15.5 Future Opportunities and Challenges
- •15.6 Conclusion
- •References
- •16.1 Fundamentals of Herbal Drug Delivery Systems
- •16.1.1 Advantages of Herbal Drugs
- •16.1.2 Challenges of Herbal Drugs
- •16.1.3 Rise of Targeted Delivery for Herbal Drugs
- •16.2 Carriers Systems for Targeted Drugs
- •16.2.1 Liposome-Mediated Drug Delivery System
- •16.2.2 Polymeric Nanoparticles as Drug Carriers
- •16.2.3 Micelles
- •16.2.4 Dendrimers
- •16.2.5 Carbon Nanotubes and Fullerenes
- •16.2.6 Phytosomes
- •16.2.7 DNA Nanocarriers for Targeted Drug Delivery
- •16.2.8 Aptamers for Drug Targeting
- •16.2.9 Microspheres and Micropellets
- •16.3 Targeting Strategies and Mechanisms
- •16.3.1 Ligand-Receptor Mediated Targeting
- •16.3.2 Antibody Drug Conjugates
- •16.3.3 Aptamers for a Targeted Delivery System for Herbal Drugs
- •16.3.4 Stimuli-Responsive Delivery Systems
- •16.4.1 Herbal Drugs for Communicable Diseases
- •16.4.2 Herbal Drugs for Communicable and Non-Communicable Diseases
- •16.5 Conclusion and Future Perspective
- •References
- •17.1 Introduction
- •17.2 An Overview of Phytomedicine
- •17.3 Application of Nanoformulation
- •17.3.1 Nanosuspension Technology
- •17.3.2 Nano-Encapsulation
- •17.3.3 Three-Dimensional Printing in Nanopharmacy (Nano Printing)
- •17.3.4 Applications in Drug Delivery Systems
- •17.3.5 Biomimetics and Bioinspiration in Nanopharmaceuticals/Nanomedicines
- •17.3.6 Green Design
- •17.4 Future study
- •17.5 Conclusion
- •References
- •18.1 Introduction
- •18.2 Herbal Phytoconstituents for Disease Management
- •18.3 Barriers to Herbal Formulations
- •18.4 Strategies to Enhance Bioavailability
- •18.5 Herbal Formulations – Conventional Dosage Forms
- •18.6 Nanocarriers in Herbal Drug Delivery
- •18.7 Clinical Status of Current Delivery Strategies
- •18.8 Conclusion
- •References
- •19.1 Introduction
- •19.1.1 Definition and Scope
- •19.1.2 History
- •19.1.3 Importance and Relevance in Modern Medicine
- •19.2 Basics of Nanotechnology and Herbal Medicines
- •19.2.1 Nanotechnology
- •19.2.2 Basics of Herbal Medicines
- •19.3 Implementing Herbal Nanomedicines
- •19.3.1 Protocols for Implementation
- •19.3.1.1 Techniques for the Preparation of Herbal Nanoparticles
- •19.3.1.2 Dosage and Administration Strategies
- •19.3.2 Documenting Patient Case Histories and its Analysis
- •19.3.2.1.1 Condition Treated
- •19.3.2.1.2 Treatment Provided
- •19.3.2.1.3 Patient Response
- •19.4 Standardized Treatment Procedures
- •19.4.1 Customization for Specific Ailments
- •19.4.2 Tailoring for Individual Patient Needs
- •19.5 Advantages of Herbal Nanomedicine in Clinical Settings
- •19.5.1 Increased Patient Adherence
- •19.5.2 Reduced Side Effects
- •19.5.3 Improved Efficacy
- •19.6 The Future of Herbal Nanomedicine in Clinical Practice
- •References
- •20.1 Herbal Nanomedicines: A Brief Overview
- •20.2 Safety Issues and Toxicological Concerns with Herbal Nanomedicines
- •20.3.1 In Vitro Methods
- •20.3.2 In Vivo Assays
- •20.3.3 Utilization of Advanced Analytical Tools
- •20.3.4 In Silico Approach: Nano-QSAR
- •20.3.5 Grouping/Read-Across Technique
- •20.3.6 Genetic Approaches
- •20.3.7 Utilization of Validated Human Cell Lines in Immunotoxicity Assays
- •20.3.8 In Vitro Carcinogenicity Assessment with Transformed Cells
- •20.3.9 DNA Barcoding
- •20.3.10 Systems Toxicology: ‘Omics’ Technology
- •20.3.11 Nano-Informatics Database
- •20.3.12 Miscellaneous Advanced Approaches in Nanotoxicology Assessment
- •20.7 Conclusion
- •Acknowledgement
- •References
- •21.1 Introduction
- •21.2 Global Regulatory Landscape
- •21.3 Regulatory Agencies and Their Roles
- •21.3.1 United States
- •21.3.1.1 Key Responsibilities of the FDA
- •21.3.2 Canada
- •21.3.3 Europe
- •21.3.3.1 European Medicine Agency
- •21.3.3.2 Key Responsibilities of the European Medicine Agency
- •21.3.3.3 Quality Guidelines of the European Medicine Agency
- •21.3.3.3.1 The Declaration of Herbal Preparations in Traditional Herbal Medicinal Products
- •21.3.3.3.2 Practices for Materials Collection from Herbal Origin
- •21.3.4 Non-Clinical Guidelines
- •21.3.4.1 Genotoxicity Assessment of Herbal Preparations
- •21.3.5 Asia
- •21.3.5.1 Traditional Chinese Medicines
- •21.3.5.2 Regulatory Approaches for TM/CM
- •21.3.6 Indian Ayurvedic Regulations
- •21.3.6.1 Food Safety and Standards Authority of India
- •21.3.7 World Health Organization
- •21.3.7.1 WHO Guidelines on the Safety Monitoring of Herbal Medicines
- •21.4 Classification of Herbal Products
- •21.4.1 Dietary Supplements
- •21.4.2 Herbal Supplements
- •21.4.3 Functional Food
- •21.4.4 Traditional Medicine
- •21.5 Approval Process
- •21.5.1 Pre-Market Approval
- •21.5.2 Post-Market Surveillance
- •21.5.3 Clinical Trials
- •21.6 Diverse Regulatory Standards
- •21.6.1 Example of Divergence
- •21.7 Efforts for International Collaboration
- •21.8 Impact of Scientific Advancements
- •21.8.1 Combination of Modern Research and Traditional Knowledge
- •21.8.2 Recognizing the Value of Traditional Knowledge
- •21.9 Approaches to Integration
- •21.9.1 Collaborative Research
- •21.9.2 Participatory Research
- •21.9.3 Interdisciplinary Research
- •21.9.4 Comparative Research
- •21.10 Challenges & Considerations
- •21.11 Advanced Technologies in Quality Control
- •21.11.1 Analytical Techniques
- •21.11.2 Good Manufacturing Practices (GMP)
- •21.11.3 Biological Assays
- •21.11.4 Standardization of Extraction Methods
- •21.11.5 Data Management & Traceability
- •21.12 Challenges & Future Directions
- •21.13 Personalized Herbal Medicine
- •21.14 Regulatory Implications
- •21.15 Sustainable and Ethical Sourcing
- •21.16 Conclusion
- •21.17 Future Outlook for the Regulatory Framework
- •References
- •22. Present Challenges and Future Perspective of the Herbal Drug Industry
- •22.1 Introduction
- •22.2 Emerging Trends and Innovations
- •22.2.1 Biotechnology and Genetic Engineering
- •22.2.2 Nanotechnology
- •22.3 Regulatory Challenges and Opportunities
- •22.4 Intellectual Property Rights
- •22.4.1 Conventional Medicine and Rights to Intellectual Property
- •22.5 Global Market Trends
- •22.6 Challenges and Limitations
- •22.7 Future Directions
- •22.8 Conclusions
- •References
- •Index


Herbal Pharmacopeia
This book comprehensively explores the intersection between traditional herbal medicine and
cutting- edge nanotechnology. The chapters introduce modern techniques used in herbal extraction
and analysis. The principles of drug discovery from plants are discussed, with a focus on the identication and development of bioactive compounds that have therapeutic potential. It discusses the
pharmacological properties, biotechnological approaches in drug development, and challenges in
the formulation and standardization of herbal medicines. Emerging trends and applications of nanotechnology in herbal pharmacotherapy, such as nanoparticle synthesis, enhanced bioavailability
using nanocarriers, safety assessments, novel and targeted delivery systems, and regulatory considerations, are thoroughly discussed. Additionally, it includes a comparative analysis of traditional
and nano- formulated approaches and their implementation in clinical settings. Towards the end, the
book reviews the regulatory considerations for herbal products and future perspectives in herbal
pharmacopeia. This book is intended for researchers, clinicians, and professionals in herbal medicine, pharmacology, and nanotechnology.
Dr. Arshad Farid currently serves as an Assistant Professor in the Gomal Center of Biochemistry
and Biotechnology, Gomal University, D.I. Khan, Pakistan. He has approximately 17 years of teaching and research experience and has supervised 13 MPhil. research students while mentoring numerous PhD candidates. Farid has more than 100+ publications of international and national repute, the
total cumulative impact factor of his published papers being 450+. His scientic activities are highly
interdisciplinary, ranging from medicinal plants, natural product chemistry, herbal drug development, and ethnopharmacology to nanotechnology, drug delivery, and microbiology. He has served
as the editor for six books accepted for publication and has written more than 50 book chapters for
various publishers. With a notable count of 27 international patents (Germany, UK, Japan, and South
Africa etc.), he has published more than 15 abstracts in national and international conference proceedings and has contributed signicantly to the scientic community by peer-reviewing for more
than 30 esteemed journals.
In 2023, Dr. Farid was a fellow of the British Council-Charles Wallace Fellowship program at the
University of Aberdeen, Scotland, UK. Prior to that, in 2007, he received a fellowship for “Training
in the Environmental, Agricultural, and Analytical Chemistry Laboratory Techniques” from the
Department of Chemistry at the University of Glasgow, Scotland, UK. He is a Research Fellow of
INTI International University.

Herbal Pharmacopeia
Nanotechnology and Advancing Drug Discovery
Edited by
Arshad Farid

First edition published 2025
by CRC Press
2385 NW Executive Center Drive, Suite 320, Boca Raton FL 33431
and by CRC Press
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN
CRC Press is an imprint of Taylor & Francis Group, LLC
© 2025 selection and editorial matter, Arshad Farid; individual chapters, the contributors
Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume
responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to
trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to
publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know
so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized
in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying,
microlming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
For permission to photocopy or use material electronically from this work, access www. copyright. com or contact the
Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. For works that are not
available on CCC please contact mpkbookspermissions@tandf.co.uk
Trademark notice: Product or corporate names may be trademarks or registered trademarks and are used only for identication
and explanation without intent to infringe.
ISBN: 978-1-032-89288-7 (hbk)
ISBN: 978-1-032-89289-4 (pbk)
ISBN: 978-1-003-54441-8 (ebk)
DOI: 10.1201/9781003544418
Typeset in Times
by SPi Technologies India Pvt Ltd (Straive)

Contents
Chapter 1 Introduction to Herbal Pharmacopeia...........................................................................1
Kushagra Sharma, Kondle Ravi, Ab Waheed Wani, Sanjeev Kumar,
and Shuja Qureshi
Chapter 2 Historical Development of Herbal Medicine .............................................................19
Roomah Javed, Maria Faraz, Arshad Farid, and Samy Selim
Chapter 3 Modern Techniques in Herbal Extraction and Analysis .............................................36
Sadaf Javaria, Muhammad Zareef, and Muhammad Nadeem
Chapter 4 Principles of Drug Discovery from Plants..................................................................65
Sayyeda Sabahat Babar, Zarghoona Jawad, Fatima Ayub,
and Muhammad Imran Khan
Chapter 5 Bioactive Compounds in Herbal Remedies ................................................................89
Raheela Sarwar, Muhammad Maisam, Muhammad Waseem Khan,
Youngbo Xue, and Said Hassan
Chapter 6 Pharmacological Properties of Herbal Drugs ........................................................... 122
Maria Faraz, Iftikhar Ahmad, Roomah Javed, Sohail Ahmad, Arshad Farid,
and Samy Selim
Chapter 7 Biotechnological Approaches for Herbal Drug Discovery ....................................... 145
Sohail Ahmad, Maria Faraz, Iftikhar Ahmad, Arshad Farid, and Samy Selim
Chapter 8 Herbal Formulation Development and Standardization ...........................................166
Rabiya Rashid, Sanjeev Kumar, Ab Waheed Wani, Anis Ahmad Mirza,
Bilal Ah Bhat, and Zarina
Chapter 9 Emerging Trends in Herbal Nanotechnology ........................................................... 188
Muhammad Sirab Khan, Muhammad Mudasar Aslam, Nida Khan,
Maha Rehman, and Nazneen Akhtar
Chapter 10 Applications of Nanotechnology in Herbal Pharmacology ......................................213
Jyoti Rani, Deepak Beniwal, Sahil Dhull, Vibhuti Gulia,
Mukul Machhindra Barwant, and Balwant Singh
v

vi Contents
Chapter 11 Nanoparticle Synthesis and Characterization for Herbal Drug Delivery .................238
Kashmala Khalid, Muhammad Abdullah Aziz, Sana Saleem,
Arshad Farid, Fati Ullah Khan, and Haza Sehrish Kiani
Chapter 12 Enhanced Bioavailability of Herbal Extracts Using Nanocarriers ...........................257
Marij Noor, Amina Khalid, Muhammad Umair, Tooba Khan,
and Muhammad Imran Khan
Chapter 13 Herbal Medicine and Neurological Diseases ...........................................................287
Sunil Kumar Kadiri, Prashant Tiwari, Samaresh Pal Roy,
and Suchismita Bhowmik
Chapter 14 Safety Assessment of Nanoparticle-Based Herbal Formulations ............................. 305
Haris Khan, Sumiya Mustafa Alvi, Muhammad Ibrahim Khan,
Hazrat Nabi, and Muhammad Imran Khan
Chapter 15 Novel Drug Delivery Methods for Herbal Medicine ................................................ 331
Mukul Machhindra Barwant, Odangowei Inetiminebi Ogidi,
Shreya Singh, and Balwant Singh
Chapter 16 Targeted Delivery Systems for Herbal Drugs ...........................................................345
Rizwan Ullah Khan, Syeda Pakeeza Fatima Naqvi, Yubao Chen,
and Sohail Ahmad
Chapter 17 Nanotechnology-Enhanced Delivery of Herbal Extract: Formulation,
Preclinical and Clinical Efciency ........................................................................... 367
Mukul Machhindra Barwant, Shreya Singh, Balwant Singh,
Shalagha Ab Sharma, and Odangowei Inetiminebi Ogidi
Chapter 18 Comparative Analysis of Traditional and Nano-Formulated Approaches
in Viability, Targeted Delivery, and Patient Outcomes ............................................. 375
J. Nithya Shree, A. Ronaldo Anuf, and Sohail Ahmad
Chapter 19 Implementing Herbal Nanomedicine in Clinical Settings with Patient
Care Histories Treatment Protocols and Observed Benets .................................... 393
Saleem Ur Rahman, Asma Zahoor, Mashaal Nageen, Afsheen Tajummal,
Ehtisham Shaque, Nasir Ali, and Farakh Javed
Chapter 20 Safety Proles and Potential Toxicological Concerns of Herbal Nanomedicine ..... 412
Sutapa Biswas Majee, Rachayeeta Bera, Dhruti Avlani, Ushasi Das,
and Sudarshan Singh

Contents vii
Chapter 21 Regulatory Considerations for Herbal Products ....................................................... 440
Saleem Ur Rahman, Ehtisham Shaque, Afsheen Tajummal,
Mashaal Nageen, Asma Zahoor, Nasir Ali, and Farakh Javed
Chapter 22 Present Challenges and Future Perspective of the Herbal Drug Industry ................458
Mehtab Yasmeen, Mukul Machhindra Barwant, Balwant Singh,
and Odangowei Inetiminebi Ogidi
Index .............................................................................................................................................. 468

Introduction to Herbal
1
Pharmacopeia
Kushagra Sharma
Department of Horticulture, Jawaharlal Nehru Krishi Vishwa Vidyalaya,
Jabalpur, India
Kondle Ravi, Ab Waheed Wani, and Sanjeev Kumar
Department of Horticulture, School of Agriculture, Lovely Professional
University, Phagwara, India
Shuja Qureshi
KVK Ganderbal, SKUAST- Kashmir, Kashmir, India
1.1 INTRODUCTION
The integration of herbal remedies into contemporary medicine underscores a profound and enduring relationship between human health and plant- based therapies. Modern pharmacopoeias, meticulously crafted to standardize medicinal products, encompass both synthetic and natural substances
[1]. Among the notable herbal pharmacopoeias are the Indian Herbal Pharmacopoeia (IHP), the
Korean Herbal Pharmacopoeia (KHP), the American Herbal Pharmacopoeia (AHP) and the British
Herbal Pharmacopoeia (BHP). Each of these resources offers detailed and rigorously reviewed
monographs on a diverse range of botanicals, including Ayurvedic, Chinese, and Western herbs. For
instance, the AHP provides an extensive repository of information on herbal medicines, serving as
an indispensable reference for academics, healthcare professionals, manufacturers, and regulators
[2]. Herbal medicines are a vital component of primary healthcare worldwide, with around 80% of
the global population depending on them for various health- related needs, as reported by the World
Health Organization (WHO) [3]. This reliance reects the swift expansion of the phytopharmaceutical industry, particularly within the dietary supplement market. Despite this growth, many supplements suffer from inadequate research and variable quality.
The relationship between traditional herbal practices and modern therapeutic applications is signicant. Of the 120 active compounds extracted from plants and employed in current medical treatments, 80% show a strong alignment with their traditional uses [4]. Usage statistics reveal that
herbal medicines are widely embraced across different regions: over 90% of individuals in Africa,
70% in India, and signicant percentages in Germany, Australia, Canada, the United States, Belgium,
and France use herbal remedies to meet their healthcare needs [5]. Economically, herbal medicines
present a compelling alternative to synthetic drugs. Developing a new synthetic drug generally takes
about 12 years and can cost roughly $230 million. In contrast, the research and development of
herbal medicines tend to be faster and more cost- effective. The global market for herbal medicines
is experiencing rapid growth, with an annual increase of over 15%, and it is projected that the trade
in herbal products in the United States will reach $70 billion by 2050 [6].
Countries in the developing world, which are rich in plant species with medicinal properties, play
a crucial role in this eld. It is estimated that around 35,000 plant species have medicinal uses, with
over 7,000 compounds in modern pharmacopoeia originating from these plants. The WHO denes
1

2 Herbal Pharmacopeia
herbs as crude plant materials used in various forms and recognizes herbal medicines as preparations
and mixtures derived from these plant materials [7].
The emergence of nanomedicine has brought revolutionary advancements to the eld, enabling
the manipulation of nanoparticles for drug development. Nanotechnology, involving particles
smaller than 100 nanometers, offers new opportunities for addressing challenges in medicine and
pharmacy. This technology enables the exact control of atoms and molecules, resulting in the creation of innovative materials and systems with distinctive properties. Recent advancements in herbal
technology showcase a rened combination of traditional knowledge and modern scientic methods
[8]. Precision farming and controlled environments optimize the cultivation of medicinal herbs,
while nanocarriers improve the targeted delivery of herbal extracts. The incorporation of articial
intelligence further speeds up drug discovery from herbal sources. This merging of ancient wisdom
with advanced science marks a new era in the development of potent herbal products and medicines,
ready to tackle current health challenges with enhanced effectiveness and understanding [3].
1.2 THE EVOLUTION OF HERBAL MEDICINE: A HISTORICAL PERSPECTIVE
Herbal medicine, as articulated in the ancient Chandogya Upanishad—“The essence of all beings
is Earth. The essence of the Earth is Water. The essence of Water is Plants. The essence of Plants
is the Human Being”—has historically unfolded along two primary trajectories. The rst trajectory
represents a tradition of simplicity where community- based practitioners, including folk healers
and familial custodians of herbal knowledge, employed medicinal plants to provide care [9]. These
practitioners, who often held a profound understanding of local ora, have played a crucial role in
maintaining health and wellness within their communities through generations. The second pathway
includes the professional medical practitioners of ancient times, who were often among the most
educated scholars of their era. This path is well recorded in foundational texts such as Dioscorides’
De Materia Medica and the Hippocratic Corpus from Greece, India’s Charaka Samhita, China’s
Shen Nong Ben Cao, and Avicenna’s Canon of Medicine from Persia. During the Renaissance, herbal
medicine was further advanced by prominent gures such as Fuchs, Gerard, Mattioli, Parkinson, and
Salmon [10]. These established medical traditions were closely linked with sophisticated concepts of
anatomy, physiology, and pathology. On the other hand, folk healing practices were rooted in hands on experience and collective community knowledge. While early Western medicine, shaped by the
humoral theories of Hippocrates, Galen, and Avicenna, has progressed and moved away from these
old frameworks, the core principles of Ayurvedic and Chinese medicine have remained steadfast.
Both systems maintain that humans are an integral part of nature and continue to evolve while adhering to their historical principles, reecting a harmonious alignment with natural processes for healing.
1.3 DIVERSITY OF HERBAL PHARMACOPOEIAS ACROSS THE GLOBE
Traditional medicines have been used worldwide for millennia, providing critical therapeutic
resources to nearly 85% of the global population and contributing substantially to contemporary
healthcare. These ancient remedies remain inuential in drug discovery, with around 46% of newly
approved drugs between 1981 and 2019 either sourced from, or inspired by, natural products [11].
During the COVID- 19 pandemic, traditional Chinese medicines played a signicant role in alleviating symptoms, slowing disease progression, and decreasing both mortality and recurrence rates.
Currently, there are over 60 recognized pharmacopoeias globally, with 42 of them (70%) including
documentation of herbs or natural products [12].
1.3.1 The IndIan PharmacoPoeIa (IP)
The Indian Pharmacopoeia (IP) is the ofcial benchmark for drug quality in India. Created by the
Indian Pharmacopoeia Commission (IPC), which operates under the Ministry of Health and Family
Welfare of the Government of India, the IP sets forth criteria for the identity, purity, and potency of

Introduction to Herbal Pharmacopeia 3
pharmaceuticals in order to guarantee their quality. The IP is periodically updated with addenda to
incorporate urgent revisions and new entries, and these updates are considered as authoritative as
the main version of the IP.
The roots of the Intellectual Property (IP) can be traced to the 1844 publication of the Bengal
Pharmacopoeia and General Conspectus of Medicinal Plants. This work concentrated on native
drugs but also featured certain European remedies. India’s inaugural ofcial pharmacopoeia was
issued in 1868, blending components from the 1867 British Pharmacopoeia with indigenous medicines [13]. After India gained independence, the Indian Pharmacopoeia Committee was established
in 1948, and it published the rst edition of the Indian Pharmacopoeia in 1955.
1.3.2 The euroPean PharmacoPoeIa (Ph. eur.)
The European Pharmacopoeia (Ph. Eur.) characterizes a herbal drug as an entire, fragmented,
or cut plant or its parts, encompassing algae, fungi, or lichens, in its natural state, which is usually dried but can occasionally be fresh [11]. It also covers specic exudates that have not been
subject to particular processing. Founded in 1964 through the Convention on the Elaboration of
a European Pharmacopoeia under the Council of Europe, the Ph. Eur. sets quality standards for
the production and regulation of medicines across Europe and has an impact on other nations,
including Moldova [9]. The 11th edition, effective from January 1, 2023, is the latest, although
the 10th edition was used in this review due to availability constraints [14]. The Ph. Eur. has
expanded its reach, with Moldova joining the Convention in 2017 and countries such as India,
Japan, and Uzbekistan becoming observer states, demonstrating its ongoing relevance and
dynamism.
In the European Pharmacopoeia (Ph. Eur.), herbal medicines are identied using a binomial
nomenclature system that includes botanical scientic names [11]. The initial term species the
genus, species, or variety, while the second term describes the type of plant part, such as
underground parts (e.g., radix, rhizome, tubera, bulbus), bark (cortex), or aerial parts (e.g.,
herba, folium, os, fructus, pseudofructus, pericarpium, semen, seminis tegumentum, gemmae).
The 10th edition of the Ph. Eur. features more than 2,500 monographs and around 370 general
texts [13]. This includes six general monographs (e.g., herbal drugs, herbal drug extracts, essential oils), 27 general texts (e.g., pesticides, heavy metals in herbal drugs, High performance thin
layer chromatography (HPTLC) of herbal drugs and preparations), and 315 individual monographs [15].
1.3.3 unITed STaTeS PharmacoPoeIa (uSP)
The United States Pharmacopoeia (USP) is a self- governing, scientic, nonprot entity committed to advancing public health by setting public standards. Its goal is to enhance global health by
guaranteeing the quality, safety, and effectiveness of medicines and food products [12]. Within the
Dietary Supplements section (Volume 3) of the USP, there are detailed monographs for herbal drugs
[7]. These monographs adhere to established nomenclature and quality control protocols, listing
herbal drug names in English and their scientic names in Latin, and specifying the minimum content of quantied constituents when relevant [16].
1.3.4 The ruSSIan FederaTIon’S STaTe PharmacoPoeIa (SPrF)
The 14th edition of the State Pharmacopoeia of the Russian Federation (SPRF), introduced in 2018,
includes 107 monographs detailing medicinal plants [15]. This edition adds 25 new monographs and
eliminates one from the 11th edition. It also covers plants which are not indigenous to Russia, which
do not have a traditional usage history, or which are commonly used in Western medicine [17]. Each
SPRF monograph presents the name of the herbal drug in both Russian and Latin. The Russian name
is given rst, followed by the Latin name, which is in the plural form.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
